|
| Press Releases |
|
 |
|
| Wednesday, September 5, 2018 |
|
|
NANOBIOTIX half year results for the six months ended June 30, 2018 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended June 30 2018, from the consolidated financial statements at June 30, 2018 that have been reviewed by the supervisory board dated September 4, 2018. more info >> |
|
| Friday, July 27, 2018 |
|
|
NANOBIOTIX signs a 40M EUR non-dilutive financing agreement with the European Investment Bank |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company launched a non-dilutive financial partnership with the European Investment Bank (EIB) to boost its research, development and innovation activities. more info >> |
|
| Friday, June 22, 2018 |
|
|
NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today positive topline results of the Phase II/III act.in.sarc trial evaluating NBTXR3 in Soft Tissue Sarcoma (STS). more info >> |
|
| Wednesday, June 6, 2018 |
|
|
NANOBIOTIX' Management Statement on Recent Share Price Variation |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, communicates today regarding the recent evolution of its share price. more info >> |
|
| Friday, May 4, 2018 |
|
|
Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today that it is launching a research collaboration with Weill Cornell Medicine to begin nonclinical studies of NBTXR3's mechanism of action. more info >> |
|
| Wednesday, April 18, 2018 |
|
|
AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that preclinical data evaluating the activation of the cGAS-STING pathway by NBTXR3 has been presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago, Illinois (April 14-18, 2018). more info >> |
|
| Wednesday, April 11, 2018 |
|
|
The University of Texas MD Anderson Cancer Center and Nanobiotix have an Agreement to Run Immunotherapeutic Pre-clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it will cooperate with The University of Texas MD Anderson Cancer Center, Houston TX, to work on NBTXR3, Nanobiotix's lead product. more info >> |
|
| Friday, March 30, 2018 |
|
|
Nanobiotix 2017 Annual Results |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2017. more info >> |
|
| Monday, January 22, 2018 |
|
|
Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces a first readout of intermediate data on the safety and feasibility in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and liver metastasis from other tumors. more info >> |
|
| Thursday, January 11, 2018 |
|
|
Nanobiotix Partners with Providence Cancer Institute to run Immunotherapeutic Preclinical Research in Pancreatic Cancers |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it will begin a pre-clinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors and activation by radiotherapy. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Hola Prime Plans to Enter Futures Trading to Solve One of Finance's Most Persistent Problems: Complexity
May 23, 2025 20:00: JST
|
|
|
Hola Prime Plans to Enter Futures Trading to Solve One of Finance's Most Persistent Problems: Complexity
May 23, 2025 19:00 HKT/SGT
|
|
|
sureWin Nominated for Best iGaming Platform 2025 in SiGMA Awards
May 23, 2025 19:00: JST
|
|
|
sureWin Nominated for Best iGaming Platform 2025 in SiGMA Awards
May 23, 2025 19:00 HKT/SGT
|
|
|
Fujitsu and Tokai National Higher Education and Research System utilize AI to accelerate clinical research and tackle 'drug loss' in Japan
May 23, 2025 17:29 JST
|
|
|
三菱商事、経営戦略2027の実現に向けた人事領域の取り組みについて発表
May 23, 2025 14:00: JST
|
|
|
Lockheed Martin and Fujitsu Strengthen Japan Industry Collaboration with SPY-7 Supplier Selection and Strategic Agreements
May 23, 2025 13:36 JST
|
|
|
NIED, Fujitsu, SDS and Mitsubishi Electric sign joint research agreement to advance Japan Disaster Charter operational framework
May 23, 2025 13:35 JST
|
|
|
Honda Expands Production Capacity by Adding New Production Line at Fourth Motorcycle Plant in India
May 23, 2025 12:17 JST
|
|
|
Honda Reaches 500 Million-Unit Milestone in Cumulative Global Motorcycle Production
May 23, 2025 11:32 JST
|
|
|
東海国立大学機構と富士通、生成AIを用いた診療データの活用により治験候補患者の選定に貢献
May 23, 2025 10:30: JST
|
|
|
Five Toyota Group Companies to Accelerate Skill Development and Innovation in AI and Software
May 23, 2025 10:51 JST
|
|
|
52TOYS即將赴港上市 打造IP玩具新標桿
May 23, 2025 07:59 HKT/SGT
|
|
|
52TOYS即将赴港上市 打造IP玩具新标杆
May 23, 2025 07:36 HKT/SGT
|
|
|
DCLI Drives Fleet Efficiencies with BlackBerry Radar Deployment Across 100,000 Chassis
May 22, 2025 19:56 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
